Our History

M2GEN: Rooted in Science and Cancer Research

M2GEN was spun out of Moffitt Cancer Center, a world-class cancer research institute, to help facilitate a collaborative approach to the fight against cancer. Founded in 2006, M2GEN’s efforts are not only disrupting the way industry researchers look for new cancer therapies, but also developing what the future holds for their approach toward precision cancer medicines.

M2GEN, Total Cancer Care, ORIEN and its leaders have been globally recognized for groundbreaking work in advancing precision medicine. M2GEN is a rapidly growing company, and we continue to expand our data product offerings and scale our capabilities to serve our partners.

woman-reading-tablet-screen

The M2GEN Timeline

timeline-desktop_2020-08-05

Our Leadership

M2GEN is led by industry trailblazers and experienced scientific experts who share the belief that the future of effective cancer research and development is rooted in collaboration.

Management Team

Photo of Helge Bastian, PhD, CEO of M2Gen

Helge Bastian, PhD

President and Chief Executive Officer of M2GEN

See Full Bio

Helge Bastian, PhD, currently serves as the president and chief executive officer of M2GEN. Dr. Bastian joins M2GEN from Thermo Fisher Scientific, Inc., where he led the Sample Preparation and Synthetic Biology businesses as Vice President & General Manager since 2014. Before Thermo Fisher Scientific, Dr. Bastian held a number of senior leadership positions and served as a member of several executive leadership teams, including Managing Director and Chief Commercial Officer at Indivumed, an integrated oncology company; Vice President Global Marketing, Business Development and Strategy at Sigma-Aldrich (now Merck KGaA); Executive Vice President Life Science Services for SGS, the world’s leading inspection, verification, testing and certification company. Prior to SGS, he held various management positions during his 11-plus years at Qiagen including Vice President Molecular Diagnostics, Vice President Global Strategic Marketing, and Vice President PreAnalytiX, a QIAGEN / Becton Dickinson joint venture. Dr. Bastian earned his diploma in biology / biochemistry from Georg-August University and holds a Ph.D. in molecular and cell biology performed at the Max-Planck Institute for Biophysical Chemistry. From 2014-2018, Dr. Bastian served as a board member to the International Gene Synthesis Consortium (IGSC). Dr. Bastian has recently been appointed to the board of directors at enzymatic gene synthesis pioneer Molecular Assemblies, Inc., San Diego, and is an alumnus from the Max-Planck-Network and the Columbia Business School.

Joseph R. Smith, CPA, CGMA

Joseph R. Smith, CPA, CGMA

Senior Vice President and Chief Financial Officer of M2GEN

See Full Bio

Joseph R. Smith, CPA, CGMA, currently serves as the senior vice president and chief financial officer for M2GEN. In this role, Joe is responsible for the financial, marketing, and sales aspects of M2GEN and provides leadership for the day-to-day financial and operational aspects of the business. Prior to joining M2GEN, Joe served as chief operating officer and chief financial officer for Bisk Education and was the CFO, secretary, and treasurer for a private, then public, dental practice management company. Joe started his career in public accounting at Deloitte, rose to the level of partner, and was in charge of the middle market practice in the Tampa, Florida office. He holds a BSBA in Accounting with Honors from University of Florida.

Todd Johnson

Todd Johnson, MD

Chief Growth Officer of M2GEN

See Full Bio

Dr. Todd Johnson is Chief Growth Officer for M2GEN. He previously served as Senior Advisor to Clayton, Dubilier & Rice in Healthcare/Real World Data, to which he brought a 20-year track record building and managing high-performing, innovative Life Sciences data and services businesses. His previous experiences include the founding and management of Optum’s Clinical Research Group, co-founding and serving as president and board member at CytoVas, a liquid biopsy company, Noble.MD, an innovative patient data platform sold to WellTrackOne, Abbott Labs/AbbVie’s pharmaceutical pipeline, and MDS / Celerion, a drug development business sold to Bain Capital. Early in his career, Dr. Johnson was a cancer biologist at the Dana-Farber Cancer Institute, and at the Peter Nowell lab at Penn. Dr. Johnson holds a Bachelor of Arts from Penn, an ABA from Oxford, an MD from the Perelman School of Medicine at the University of Pennsylvania, and an MBA from Wharton.

Wilf Russell

Wilf Russell

Chief Technology Officer of M2GEN

See Full Bio

Wilf Russell is a technical visionary and a high-performing senior executive that brings years of experience and business acumen providing a competitive edge to companies from enterprise to SMBs. His ability to scale, organize, and envision technical strategies amplify unique growth initiatives aligned to changing and accelerating market realities and business expectations. With over 25 years of experience in the software industry building and managing technical organizations across a number of industry verticals, Wilf has been responsible for delivery of a wide range of products from mobile apps through highly scalable, cloud-based services and platforms. During his career he has been a leader in a diverse selection of organizations with differing LOB and P&L objectives -- CTO of Nike, Chief Architect of Volvo, the Office of the CTO at Microsoft and IGT, Myspace, Microsoft Research, and RealNetworks – managing large scale operating and capital budgets. Coupled with a strong and clear technical vision and leading organizations of 1500+ employees worldwide, Wilf continues to invest in knowledge with a thirst for technology and partners with executive leadership to drive a cohesive engineering roadmap and clear objectives aligned against business and corporate strategies.

M2GenManagementTeamPhoto_GaryOliver

Oliver Hampton, PhD

Vice President, Bioinformatics and Biostatistics of M2GEN

See Full Bio

Oliver Hampton, PhD, currently serves as the vice president of Bioinformatics and Biostatistics for M2GEN. Oliver leads the bioinformatics team and is building the biostatistics team to support the Avatar project, as well as collaborative projects between M2GEN, Pharma and ORIEN partners. Oliver comes to M2GEN with great expertise in Next-Generation-Sequencing, having led the Platform Informatics team, Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center. Prior to that, Oliver was an Assistant Professor at Baylor College of Medicine.

Liza_Bryant_m2gen-leadership-photo

Liza Bryant, PHR

Director, Human Resources of M2GEN

See Full Bio

Liza Bryant, PHR serves as the Director of Human Resources at M2GEN.  Liza has over 10 years of HR leadership experience with various companies, including healthcare, consulting and PEO, and has held roles such as Senior Director, HR, Senior HR Manager, HR Business Partner and HR Consultant. 

Liza is experienced in employee relations, employment law compliance, leadership, team management and culture development, building and developing HR functions, organizational structure and strategic staffing, compensation, benefits, performance management and talent acquisition.   Liza was a 2019 Tampa Bay Business Journal HR Honoree, is an active member of SHRM and HR Tampa, a member of HR Inspire - HR Tampa’s Workforce Readiness Committee, and an Education Board Member for Recruiter Networking Group (RNG), Tampa.  Liza has a Professional HR certification through HRCI, and is an honors graduate of the University of South Florida with a Bachelor of Arts in Communication.

Board of Directors

Sandra E. Peterson

Chair of the Board - M2GEN & Partner, Clayton, Dubilier & Rice

See Full Bio

Ms. Peterson joined CD&R in 2019. Prior to CD&R, she was group worldwide chairman of Johnson & Johnson, where she led the consumer and medical devices businesses and was responsible for the corporation’s global supply chain, as well as its technology strategy and operating infrastructure. She currently serves as Chairman of Cynosure. Previously, Ms. Peterson served as CEO of Bayer CropScience AG, CEO of Bayer Medical Care, and president of Bayer HealthCare AG’s Diabetes Care Division. She started her career at McKinsey and has held executive positions at Medco Health Solutions (formerly known as Merck-Medco), Nabisco, and Whirlpool. Ms. Peterson is a member of the Microsoft Board of Directors, chairman of the board of the American Academy in Berlin, and on the board of the Institute for Advanced Study, the world-renowned center for science and humanities research in Princeton, NJ. Ms. Peterson is also on the boards of Covetrus (Nasdaq:CVET), Zymergen, and Volastra. She has appeared on Fortune magazine’s list of most powerful women numerous times and was featured on the magazine’s inaugural list of leaders changing healthcare. She holds an M.P.A. in applied economics from Princeton University and a B.A. in government from Cornell University.

Sarah Kim

Partner - Clayton, Dubilier & Rice (CD&R)

See Full Bio

Ms. Kim joined CD&R in 2008. She played a key role in the Firm’s investments in and subsequent sales of Diversey and naviHealth, the public and secondary offerings of HD Supply and ServiceMaster, and the Firm's investment in Covetrus. Previously, she held positions at private equity firms Metalmark Capital and McCown De Leeuw & Co. and worked in the investment banking division of Goldman Sachs & Co. She currently serves on the board of Huntsworth, a leading provider of specialty services to pharmaceutical and biotech companies. She holds an M.B.A. from Harvard Business School, a J.D. from Harvard Law School (J.D.), and a B.A. in economics and political science from Yale University.

Helge Bastian, PhD

President and Chief Executive Officer - M2GEN

See Full Bio

Helge Bastian, PhD, currently serves as the president and chief executive officer of M2GEN. Dr. Bastian joins M2GEN from Thermo Fisher Scientific, Inc., where he led the Sample Preparation and Synthetic Biology businesses as Vice President & General Manager since 2014. Before Thermo Fisher Scientific, Dr. Bastian held a number of senior leadership positions and served as a member of several executive leadership teams, including Managing Director and Chief Commercial Officer at Indivumed, an integrated oncology company; Vice President Global Marketing, Business Development and Strategy at Sigma-Aldrich (now Merck KGaA); Executive Vice President Life Science Services for SGS, the world’s leading inspection, verification, testing and certification company. Prior to SGS, he held various management positions during his 11-plus years at Qiagen including Vice President Molecular Diagnostics, Vice President Global Strategic Marketing, and Vice President PreAnalytiX, a QIAGEN / Becton Dickinson joint venture. Dr. Bastian earned his diploma in biology / biochemistry from Georg-August University and holds a Ph.D. in molecular and cell biology performed at the Max-Planck Institute for Biophysical Chemistry. From 2014-2018, Dr. Bastian served as a board member to the International Gene Synthesis Consortium (IGSC). Dr. Bastian has recently been appointed to the board of directors at enzymatic gene synthesis pioneer Molecular Assemblies, Inc., San Diego, and is an alumnus from the Max-Planck-Network and the Columbia Business School.

Gregory Dorn, MD, MPH

President - Hearst Health

See Full Bio

Greg Dorn is the president of Hearst Health, overseeing FDB (First Databank), Zynx Health, MCG, and Hearst Health International, and serves as a director of Homecare Homebase MedHOK, M2Gen, Hearst Health Ventures, and the Hearst Health Innovation Lab.

The mission of the Hearst Health network is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Each year in the US, care guidance from the Hearst Health network reaches 84% of discharged patients, 177 million insured individuals, 60 million home health visits, and 3.1 billion dispensed prescriptions.

For more than 2 decades, Dorn has been focused on raising the standard of excellence for patient care across the healthcare spectrum, through clinically rigorous guidance delivered by efficient, scalable technology. He is the co-inventor of 2 patented healthcare software technologies that continue to be used in health systems across the US. His expertise is in developing and commercializing inventive and disruptive solutions that improve care quality and efficiency.

Dorn has held a variety of leadership positions across Hearst, including chief operating officer of Zynx Health and president of FDB. In 2013 he was appointed an executive vice president of Hearst Business Media and continues to serve in that role. He is also a vice president of Hearst.

Dorn received his medical doctorate from the Columbia University College of Physicians and Surgeons and his bachelor's degree from the Columbia University School of Engineering. He performed his clinical training at UCLA, where he also obtained his master’s degree in health services management.

Edmondo Robinson, MD, MBA, FACP

Senior Vice President/Chief Digital Innovation Officer

See Full Bio

Edmondo Robinson, MD, MBA, FACP, serves as the Senior Vice President and Chief Digital Innovation Officer for Moffitt Cancer Center. This newly created position is critical to Moffitt’s success navigating a continually evolving health care industry. Dr. Robinson is responsible for expanding Moffitt’s ecosystem from within and outside of health care to deliver on consumer-oriented, real-world solutions for clinical practice, research and administrative processes essential to support growth and competitive advantage. He also oversees Moffitt’s portfolio of digital innovation, including the development and commercialization of health products, tools and technology. With this role, Moffitt aims to create and test new services, programs, partnerships and technologies that leverage digital innovations, while challenging the status quo to reduce the cost of care, improve quality, increase access to care, and enhance the patient experience.

Previously, Dr. Robinson was the Chief Transformation Officer and Senior Vice President of Consumerism at ChristianaCare, one of the largest health systems in the mid-Atlantic. He was responsible for the transformation of health care delivery to advance population health initiatives and the move from volume-based to value-based care with a special focus on developing and managing ChristianaCare’s consumerism and digital strategies.

Dr. Robinson is an associate professor of medicine at Thomas Jefferson University’s Sidney Kimmel Medical College an adjunct senior fellow in the Leonard Davis Institute of Health Economics at the University of Pennsylvania. He is also a fellow of the American College of Physicians and a senior fellow of the Society of Hospital Medicine. He holds a medical degree from the David Geffen School of Medicine at the University of California, Los Angeles; an MBA with an emphasis in health care management from the Wharton School at the University of Pennsylvania; and a master’s degree in health policy research also from the University of Pennsylvania.

Board Observer

Raphael Pollock, MD, PhD, FACS

Director, the Ohio State University Comprehensive Cancer Center Kathleen Wellenreiter Klotz Chair in Cancer Research

See Full Bio

Raphael E. Pollock, MD, PhD was born in Chicago, IL in 1950. He is a graduate of Oberlin College in Oberlin, OH, where he majored in history. This was followed by medical school at St. Louis University, St. Louis; MO, residency training in general surgery at Rush-Presbyterian-St. Luke’s Medical Center and the University of Chicago Hospitals and Clinics, Chicago, IL; followed by fellowship training in surgical oncology at the University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Pollock was invited to join the MD Anderson faculty in 1984 upon completion of fellowship training. While serving as an assistant professor of surgery, Dr. Pollock began graduate studies at the University of Texas Health Science Center/Houston, Graduate School of Biomedical Sciences, culminating in receipt of the PhD in tumor immunology in 1990. In 1993 Dr. Pollock began service as chairman of the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, a position that he held until 2010. In 1996, service as head of the Division of Surgery at the University of Texas MD Anderson Cancer Center was begun, a position entailing supervisory relationships with all 7 surgical specialty departments at that institution. In 2013 Dr. Pollock was recruited to Ohio State University as professor and director of the Division of Surgical Oncology and Chief of Surgical Services at the James Comprehensive Cancer Center. This was followed by appointment in 2015 as Surgeon in Chief, the James Comprehensive Cancer Center and Surgeon in Chief, the Ohio State University Health System. In 2017, Dr. Pollock was appointed to his current position as professor and director of the Ohio State University Comprehensive Cancer Center.

Dr. Pollock’s clinical and laboratory research work focuses on soft tissue sarcoma, a rare tumor system of connective tissue origin. He has been the recipient as principal investigator of an NIH/NCI K08 Clinician-Investigator Award (1984-89), an NIH/NCI R29 FIRST Award (1989-1994), an NIH/NCI R01 Award (1995-2007), and NIH/NCI T32 Training Grant (1999-2010), and an NIH/NCI SPORE award (2012-2017). He is married to Dina Lev, MD, a Professor of Surgery at Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel. They have 5 children: Jessica, a medical student at the Ohio State University College of Medicine; Samuel and Eden, students at the Ohio State University College of Arts and Sciences; and Noam and Omer, who are in high school in Tel Aviv, Israel.

Interested in Joining the M2GEN team?

Learn More